Narrow your search

Library

KU Leuven (2)

Odisee (2)

Thomas More Kempen (2)

Thomas More Mechelen (2)

UCLL (2)

VIVES (2)

LUCA School of Arts (1)

UGent (1)

ULB (1)

ULiège (1)


Resource type

book (2)


Language

English (2)


Year
From To Submit

2020 (2)

Listing 1 - 2 of 2
Sort by

Book
Adverse Events : Race, Inequality, and the Testing of New Pharmaceuticals
Author:
ISBN: 147986143X 1479877999 Year: 2020 Publisher: New York : New York University Press,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Explores the social inequality of clinical drug testing and its effects on scientific resultsImagine that you volunteer for the clinical trial of an experimental drug. The only direct benefit of participating is that you will receive up to.


Book
Phase I oncology drug development
Authors: --- ---
ISBN: 3030476820 3030476812 Year: 2020 Publisher: Cham, Switzerland : Springer,

Loading...
Export citation

Choose an application

Bookmark

Abstract

This book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials. The book covers strategies to accelerate the development of novel antitumor compounds from the laboratory to clinical trials and beyond through the use of innovative mechanism-of-action pharmacodynamic biomarkers and pharmacokinetic studies. The reader will learn about all aspects of modern phase I trial designs, including the incorporation of precision medicine strategies, and approaches for rational patient allocation to novel anticancer therapies. Circulating biomarkers to assess mechanisms of response and resistance are changing the way we are assessing patient selection and are also covered in this book. The development of the different classes of antitumor agents are discussed, including chemotherapy, molecularly targeted agents, immunotherapies and also radiotherapy. The authors also discuss the lessons that the oncology field has learnt from the development of hematology-oncology drugs and how such strategies can be carried over into therapies for solid tumors. There is a dedicated chapter that covers the specialized statistical approaches necessary for phase I trial designs, including novel Bayesian strategies for dose escalation. This volume is designed to help clinicians better understand phase I clinical trials, but would also be of use to translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. It could also be of use to phase I trial study coordinators, oncology nurses and advanced practice providers. Other health professionals interested in the treatment of cancer will also find this book of great value. .

Keywords

Oncology  . --- Radiotherapy. --- Oncology. --- Radiation therapy --- Electrotherapeutics --- Hospitals --- Medical electronics --- Medical radiology --- Therapeutics, Physiological --- Phototherapy --- Tumors --- Radiological services --- Antineoplastic agents --- Cancer --- Drug development. --- Design. --- Chemotherapy. --- Development of drugs --- Drugs --- New drug development --- Pharmacology --- Pharmacy --- Anticancer agents --- Antineoplastic drugs --- Antineoplastics --- Antitumor agents --- Antitumor drugs --- Cytotoxic drugs --- Inhibitors, Neoplasm --- Neoplasm inhibitors --- Development --- Treatment --- Chemotherapy --- Antineoplastic Agents. --- Drug Development. --- Neoplasms --- Clinical Trials, Phase I as Topic. --- drug therapy. --- Clinical Trials, Phase 1 --- Drug Evaluation, FDA Phase 1 --- Drug Evaluation, FDA Phase I as Topic --- Evaluation Studies, FDA Phase 1 --- Human Microdosing Trials --- Microdosing Trials, Human --- Phase 1 Clinical Trials --- Clinical Trials, Phase I --- Drug Evaluation, FDA Phase I --- Evaluation Studies, FDA Phase I --- Human Microdosing Trial --- Phase 1 Clinical Trial --- Phase I Clinical Trial --- Phase I Clinical Trials --- Microdosing Trial, Human --- Trial, Human Microdosing --- Trials, Human Microdosing --- Nontherapeutic Human Experimentation --- Medication Development --- Pharmaceutical Development --- Computational Prediction of Drug-Target Interactions --- Drug Target Prediction --- Development, Drug --- Development, Medication --- Development, Pharmaceutical --- Drug Target Predictions --- Prediction, Drug Target --- Target Prediction, Drug --- Anticancer Agents --- Antineoplastic Drugs --- Antitumor Agents --- Antitumor Drugs --- Cancer Chemotherapy Agents --- Cancer Chemotherapy Drugs --- Chemotherapeutic Anticancer Agents --- Chemotherapeutic Anticancer Drug --- Anticancer Agent --- Antineoplastic --- Antineoplastic Agent --- Antineoplastic Drug --- Antitumor Agent --- Antitumor Drug --- Cancer Chemotherapy Agent --- Cancer Chemotherapy Drug --- Agent, Anticancer --- Agent, Antineoplastic --- Agent, Antitumor --- Agent, Cancer Chemotherapy --- Agents, Anticancer --- Agents, Antineoplastic --- Agents, Antitumor --- Agents, Cancer Chemotherapy --- Agents, Chemotherapeutic Anticancer --- Chemotherapy Agent, Cancer --- Chemotherapy Agents, Cancer --- Chemotherapy Drug, Cancer --- Chemotherapy Drugs, Cancer --- Drug, Antineoplastic --- Drug, Antitumor --- Drug, Cancer Chemotherapy --- Drug, Chemotherapeutic Anticancer --- Drugs, Antineoplastic --- Drugs, Antitumor --- Drugs, Cancer Chemotherapy --- Cytotoxins --- Interferon Inducers --- Anticarcinogenic Agents

Listing 1 - 2 of 2
Sort by